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Abstract: 
Objective: To estimate the Forns index to predict fibrosis in patients with chronic liver disease at tertiary care hospital  
Patients and Methods: Total Fifty patients, of 12 to 50 years either gender had chronic liver disease by positive HCV 
RNA PCR and/or HBsAg, and had liver biopsy done for evaluation purposes were enrolled and entered in this six months 
cross sectional study after informed consent. The brief history was taken and relevant clinical examination was performed 
while the laboratory investigations include latelet count, γ-glutamyl transferase (GGT), and cholesterol levels. The Forns’ 
index will be calculated through the following equation Forns index = 7.811 – 3.131 x ln platelet + 0.781 x ln GGT + 
3.647 x ln age - 0.014 x cholesterol; the Forns score <4.2 excludes the liver cirrhosis / fibrosis. The data was saved on 
pre-designed proforma while the SPSS 16 was used to analyze the data and to manipulate the mean ±SD, frequencies and 
percentages. 
Results: During six months study period total fifty patients with chronic liver disease were evaluate for cirrhosis and 
fibrosis by non invasive indirect markers (Forns index). The mean ± for age (years) & duration of chronic liver disease 
(years) for whole population was 38.94±5.62 & 5.81±2.95 respectively. The Forns’ index (>4.2) was detected in 36 (72%) 
patients with chronic liver disease (CLD). 
Conclusion: The Forns index is accurate noninvasive blood test to predict the existence or absence of significant liver 
fibrosis in patients with chronic liver disease. 
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INTRODUCTION:  
Chronic viral hepatitis is an important cause of 
morbidity & mortality, the situation is particularly 
precarious in the developing countries and estimated 
that by the year 2020 [1,2], there will be threefold 
increase in liver cirrhosis and hepatoma from HBV 
and HCV [3]. In chronic viral hepatitis the prognosis 
and management are highly dependent on the severity 
of liver fibrosis [4]. Though the gold standard; the 
liver biopsy is far from perfect and has significant 
limitations. This has led researchers to look for other 
methods to evaluate the liver fibrosis and staging 
through noninvasive markers which are widely used 
alternative to liver biopsy [5, 6] 
Forns & colleagues estimates the fibrosis index 
(Forns’ index) consists of γ-glutamyl transferase 
(GGT), platelet count & serum cholesterol level with 
positive predictive value and 96% negative predictive 
value as 96% and 66% to detecting the significant 
liver fibrosis respectively [7-9]. The former study 
evaluates the role of non invasive marker (Forns’ and 
APRI index) in patients with chronic viral hepatitis 
and HIV [10]. The medications that impaired the 
lipid abnormalities and platelet counts can be the 
matter of concern and leads to half of the patients 
remains left unclassified [11- 13]. Thus, the present 
study used non invasive marker top predict cirrhosis / 
fibrosis in patients with CLD as early evaluation can 
save the patients from various life threatening 
complications associated with liver cirrhosis. 
 
PATIENTS AND METHODS:  
Total Fifty patients, of 12 to 50 years either gender 
had chronic liver disease by positive HCV RNA PCR  
 
and/or HBsAg, and had liver biopsy done for 
evaluation purposes were enrolled and entered in this 
six months cross sectional study after informed 
consent at tertiary care teaching hospital. The 
individuals had increased ALT for more than six 
months, whose PCR remained positive after antiviral 
therapy were also enrolled, provided had liver biopsy 
performed within the last six months. The exclusion 
criteria of the study were the patients with chronic 
liver disease other than viral origin, decompensated 
cirrhosis (Child-Pugh class C), already on antiviral 
therapy and PCR negative after treatment and the 
patients with insufficient liver biopsy specimen. The 
brief history was taken and relevant clinical 
examination was performed while the laboratory 
investigations include γ-glutamyl transferase (GGT), 
platelet count & cholesterol levels. The Forns’ index 
will be calculated through the following equation 
Forns index = 7.811 – 3.131 x ln platelet + 0.781 x ln 
GGT + 3.647 x ln age - 0.014 x cholesterol; the Forns 
score <4.2 excludes the liver fibrosis / cirrhosis. The 
data was saved on pre-designed proforma. The SPSS 
16 was used to analyze the data and to manipulate the 
mean ±SD, frequencies and percentages. 
 
RESULTS:  
During six months study period total fifty patients 
with chronic liver disease were evaluate for cirrhosis 
and fibrosis by non invasive indirect markers (Forns 
index). The mean ± for age (years) & duration of 
chronic liver disease (years) for whole population 
was 38.94±5.62 & 5.81±2.95 respectively. The 
demographical and clinical profile of study 
population is presented in Table 1. 
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TABLE 01: THE DEMOGRAPHICAL AND CLINICAL PROFILE OF THE PATIENTS 
 
AGE (years) FREQUENCY (N=50) PERCENTAGE (%) 
12-19 12 24 
20-29 13 26 
30-39 17 34 
40-50 08 16 
   
GENDER   
Male 27 54 
Female 23 46 
   
RESIDENCE   
Urban 30 60 
Rural 20 40 
   
Duration of CLD (years)   
<1  05 10 
1-3 18 36 
3-5 21 42 
≥5 06 12 
   
Etiology of CLD   
Hepatitis B 12 24 
Hepatitis C 32 64 
Hepatitis B and C 06 12 
   
Forns index (>6.9)    
Yes 36 72 
No 14 28 
   
Cirrhosis /Fibrosis   
Yes 36 72 
No 14 28 
 
DISCUSSION:  
Forns X, et al [14], observed an index based on four 
readily available variables; γ glutamyl transferase, 
platelet count, cholesterol levels & age confined to 
subjects with chronic liver disease & constructed a 
simple score system applying a constant to the 
obtained formula and set cut of values for 
considering the probability of low or high significant 
fibrosis. Hence this noninvasive tool can detect the 
minimal and progressive liver fibrosis [11]. The 
subjects with chronic viral hepatitis C without liver 
fibrosis can be detected with this panel and liver 
biopsy can be avoided in more than one third of the 
subjects while the one major advantage of the index 
is the use of very basic clinical tools [15]. In 
comparing with the study by Imbert-Bismut 
(Fibrotest) [16] some of the parameters used can 
provide a high level of certainty for the existence or 
non existence of significant liver fibrosis, but the 
usefulness may be countered by the realities that 
some of the predictive research tools (α2 
macroglobulin, haptoglobin & apolipoprotein A1) not 
readily available and easily accessible in routine 
clinical practice at majority of the hospitals. 
Moreover, the patient population studied in the 
Imbert-Bismut study [16] consists of high proportion 
of subjects with severe hepatitis C infection, as 
indicated by existence of significant fibrosis around 
40% of the individuals. In our series significant 
cirrhosis & fibrosis detected in 36 (72%) of the 
patients a figure consistent to former study & nearer 
to the spectrum of the disease burden in the 
community level. [14]. Furthermore, the index can be 
comparable to the Fibrotest and observed that the 
findings of Forns index are reproducible but has 
slightly less performance than Fibrotest [17]. Major 
caveats of Forns index include impact of 
dyslipidemia in subjects with chronic liver disease 
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[18], cholesterol impaired medications & the platelet 
estimations reproducibility. The Forns index was 
better in the prediction of significant fibrosis; it is 
easily reproducible, based on easily accessible and 
available blood tests and along with the combination 
of other markers may avoid the need for liver biopsy 
[19, 20]. 
 
CONCLUSION:  
The Forns index is convenient noninvasive serum 
marker to predict the absence or existence of 
significant liver fibrosis in patients with chronic liver 
disease. 
 
REFERENCES: 
1.Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon 
MB. Pulmonary-Hepatic vascular Disorders (PHD). 
Eur Respir J 2004;24(5):861–80. 
2.Mendez-Sanchez N, Villa AR, Chavez-Tapia NC, 
Ponciano-Rodriguez G, Almeda Valdes P, Gonzalez 
D, et al. Trends in liver disease prevalence in Mexico 
from 2005 to 2050 through mortality data. Ann 
Hepatol 2005;4:52-5. 
3.National Center for Health Statistics. National Vital 
Statistics Report. Chronic liver disease / cirrhosis 
[online] 2009 Mar 06 [cited 2017 Oct 10]. Available 
from URL: 
http://www.cdc.gov/nchs/fastats/liverdis.htm 
4.Maqsood S, Saleem A, Iqbal A, Butt JA. 
Precipitating factors of hepatic encephalopathy: 
Experience at Pakistan Institute of Medical Sciences 
Islamabad. J Ayub Med Coll Abbottabad 2006; 
18(4): 57-61. 
5 Halfon P, Munteanu M, Poynard T. FibroTest-
ActiTest as a non-invasive marker of liver fibrosis. 
Gastroenterol Clin Biol.2008;32(6):22-39. 
6 Nadeem M, Yousaf MA, Zakaria M, Hussain T, Ali 
N. The value of clinical signs in diagnosis of 
cirrhosis. Pak J Med Sci.2005;21:121-4 
7. Guzelbulut F, Cetınkaya ZA, Sezıklı M, Yasar B, 
Ozkara S, Ovunc AO. AST-platelet ratio index, Forns 
index and FIB-4 in the prediction of significant 
fibrosis and cirrhosis in patients with chronic 
hepatitis C. Turk J Gastroenterol. 2011 
Jun;22(3):279-85. 
8.Kayadibi H, Yasar B, Ozkara S, Serdar MA, 
Kurdas OO, Gonen C. The diagnostic accuracy of the 
Forns index, platelet count and AST to Platelet Ratio 
Index derived fibrosis index for the prediction of 
Hepatitis C virus-related significant liver fibrosis and 
cirrhosis. Scand J Clin Lab Invest. 2014 
Apr;74(3):240-7. 
9.Papastergiou V, Tsochatzis E, Burroughs AK. Non-
invasive assessment of liver fibrosis. Ann 
Gastroenterol. 2012; 25(3): 218–231. 
10.Bourliere M, Penaranda G, Renou C, Botta-
Fridlund D, Tran A, Portal I, et al. Validation and 
comparison of indexes for fibrosis and cirrhosis 
prediction in chronic hepatitis C patients: proposal 
for a pragmatic approach classification without liver 
biopsies. J Viral Hepat. 2006 Oct;13(10):659-70. 
11.Afdhal NH, Nunes D. Evaluation of liver fibrosis: 
a concise review. Am J Gastro 2004; 99; 1160-1174. 
12.Castera L, Pawlotsky JM. Noninvasive diagnosis 
of liver fibrosis in patients with chronic hepatitis C. 
Medscape Gen Med. 2005; 7(4):39. 
13.Sebastiani G, Alberti A. Noninvasive fibrosis 
biomarkers reduce but not substitute the need for 
liver biopsy. World J Gastroenterol 
2006;12(23):3682-3694. 
14.Forns X, Ampurdanes S, Llovent JM, et al. 
identification of chronic hepatitis C patients without 
hepatic fibrosis by a simple predictive model. 
Hepatology 2002; 36: 986-92. 
15.Ichino N, Osakabe K, Nishikawa T. A new index 
for non-invasive assessment of liver fibrosis. World J 
Gastroenterol. 2010 Oct 14; 16(38): 4809–4816. 
16.Imbert-Bismut F, Ratziu V, Pieroni L, et al. 
Biochemical markers of liver fibrosis in patients with 
hepatitis C virus infection: a prospective study. 
Lancet 2001; 357: 1069-75. 
17.Wai CT, Greenson JK, Fontana RJ, et al. A simple 
noninvasive index can predict both significant 
fibrosis and cirrhosis in patients with chronic 
hepatitis C. Hepatology 2003; 38: 518-26. 
18.Thabut D, Simon M, Myers RP, et al. Noninvasive 
prediction of fibrosis in patients with chronic 
hepatitis C. Hepatology 2003; 37: 1220-1. 
19.Hassan EM, Omran DA, El Beshlawey ML, Abdo 
M, El Askary A. Can transient elastography, Fib-4, 
Forns Index, and Lok Score predict esophageal 
varices in HCV-related cirrhotic patients?. 
Gastroenterologia y hepatologia. 2014 Feb 
28;37(2):58-65. 
20.Kayadibi H, Yasar B, Ozkara S, Serdar MA, 
Kurdas OO, Gonen C. The diagnostic accuracy of the 
Forns index, platelet count and AST to Platelet Ratio 
Index derived fibrosis index for the prediction of 
Hepatitis C virus-related significant liver fibrosis and 
cirrhosis. Scandinavian journal of clinical and 
laboratory investigation. 2014 Apr 1;74(3):240-7. 
 
 
 
